Pharmacokinetics of conivaptan hydrochloride, a vasopressin V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study

2009 ◽  
Vol 31 (7) ◽  
pp. 1542-1550 ◽  
Author(s):  
Zhongping Lily Mao ◽  
Dennis Stalker ◽  
James Keirns
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Receptor Antagonist ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
V2 Receptor ◽  
V2 Receptor Antagonist

An Open-Label Study of Nefazodone Treatment of Major Depression in Patients with Congestive Heart Failure

2003 ◽  
Vol 48 (10) ◽  
pp. 695-701 ◽  
Author(s):  
François Lespérance ◽  
Nancy Frasure-Smith ◽  
Marc-André Laliberté ◽  
Michel White ◽  
Sylvain Lafontaine ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Major Depression ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs

1994 ◽  
Vol 267 (6) ◽  
pp. H2245-H2254 ◽  
Author(s):  
M. Naitoh ◽  
H. Suzuki ◽  
M. Murakami ◽  
A. Matsumoto ◽  
K. Arakawa ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cardiac Output ◽  
Plasma Concentration ◽  
Oral Administration ◽  
Receptor Antagonist ◽  
Conscious Dogs ◽  
Hemodynamic Responses ◽  
Combined Administration ◽  
V2 Receptor

Rapid right ventricular pacing could induce congestive heart failure in conscious dogs with significant increase in plasma concentration of arginine vasopressin (AVP) (from 1.2 +/- 0.2 to 3.4 +/- 0.6 pg/ml). In this experimental model of heart failure, oral administration of the selective AVP V1 receptor antagonist OPC-21268 significantly increased cardiac output and improved renal function without significant changes in serum electrolytes and hormones. Oral administration of the selective AVP V2 receptor antagonist OPC-31260 induced marked water diuresis, which resulted in significant increases in serum sodium concentration, plasma renin activity, and plasma concentration of AVP, although it did not produce hemodynamic improvement. Combined administration of OPC-21268 and OPC-31260 showed supra-additive hemodynamic responses as well as additive renal and metabolic responses, i.e., it showed prolonged decrease in mean arterial pressure and profound increase in cardiac output. These results suggest that AVP plays a significant role in elevation of vascular tone through V1 receptors and plays a major role in retaining free water through V2 receptors in this model of heart failure. Furthermore, combined administration of V1 and V2 receptor antagonists could induce not only metabolic and hormonal responses but also more beneficial hemodynamic responses than those observed following treatment with V1 receptor antagonist alone.

Sign in / Sign up

Export Citation Format

Share Document